NIAID Now

4 Results

Scientists Identify Interferon-gamma as Potential SARS-CoV-2 Antiviral

Conditioning the lungs with interferon-gamma, a natural immune system protein best known for fighting bacterial infections, appears to be a strong antiviral for SARS-CoV-2, which causes COVID-19

The STOMP trial evaluates an antiviral for mpox

NIAID launched the STOMP trial to determine whether the antiviral drug tecovirimat can safely and effectively treat mpox. Watch Dr. Cyrus Javan of NIAID's Division of AIDS explain the importance of the STOMP trial.

Hepatitis B and C—A Closer Look at NIAID Research to Accelerate Elimination

Viral hepatitis is an inflammatory liver disease caused by infection with any of the known hepatitis viruses—A, B, C, D, and E. Most of the global viral hepatitis burden is from hepatitis B and C, which affect 354 million people and result in 1.1 million deaths annually. The Centers for Disease Control and Prevention estimates that in 2020 there were 14,000 and 50,300 new acute infections of...

NIH Continues Investment in HIV Prevention, Therapy and Cure with $34 Million Award

The National Institutes of Health has awarded approximately $34 million annually over the next five years to fund six independent Centers for HIV Structural Biology

Contact

Contact the NIAID Media Team.
301-402-1663

niaidnews@niaid.nih.gov